Kanna Health announces FDA and MHRA approvals to begin its Phase 1 clinical trial for the development of KH-001 as first FDA-approved treatment for premature ejaculation

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

KannaHealth-Treatment

More Like This

Ketabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At American Society Of Clinical Psychopharmacology Annual Meeting

Ketabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At ECNP Congress 2024

Head-to-head Trial of Prolonged-Release Oral Ketamine Formulation, KET01, and Intranasal SPRAVATO®, Finds Less Incidence of Dissociation or Cardiovascular Effects with Oral Treatment, at doses used for Treatment-Resistant Depression

Calliditas announces filing with UK MHRA for Kinpeygo in IgA nephropathy

Lecanemab licensed for adult patients in the early stages of Alzheimer’s disease

PR Newswire associated0

Alzheimer's Association Commends United Kingdom's Approval of Leqembi, But Condemns Decision to Deny NHS Access

PR Newswire associated0

Lykos Therapeutics Announces Completion of European Phase 2 Study for MDMA-Assisted Therapy for PTSD

STADA and Calliditas announce the filing for full marketing authorization of Kinpeygo® in the EU